Company: Pfizer Inc.
Ticker: PFE
Form: 10-K
Filed: 2026-02-26
Fiscal Period: {"fp": "FY", "fy_curr": 2025, "fy_prev": 2024}

Question: By what percentage did Pfizer Inc.'s net income change from fiscal year 2024 to fiscal year 2025?
Question Type: temporal_comparison

Concept: NetIncomeLoss
Answer (Numeric): -3.24
Answer (Display): -3.24%
Unit: percent_change

Evidence:
[{"chunk_id": "210", "equivalent_chunk_ids": ["210"], "section": "Consolidated Statements of Operations", "supports": ["current", "previous"], "text": "Pfizer Inc. and Subsidiary Companies\nYear Ended December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\nRevenues:\nProduct revenues\n51,663\n53,816\n50,914\nAlliance revenues\n9,266\n8,388\n7,582\nRoyalty revenues\n1,650\n1,423\n1,058\nTotal revenues\n62,579\n63,627\n59,553\nCosts and expenses:\nCost of sales\n(a), (b)\n16,067\n17,851\n24,954\nSelling, informational and administrative expenses\n(a)\n13,794\n14,730\n14,771\nResearch and development expenses\n(a)\n10,437\n10,822\n10,679\nAcquired in-process research and development expenses\n1,613\nAmortization of intangible assets\n4,874\n5,286\n4,733\nRestructuring charges and certain acquisition-related costs\n1,550\n2,419\n2,943\nOther (income)/deductions––net\n6,724\n4,388\nIncome from continuing operations before provision/(benefit) for taxes on income\n7,520\n8,023\n1,058\nProvision/(benefit) for taxes on income\n1,115\nIncome from continuing operations\n7,787\n8,051\n2,172\nDiscontinued operations––net of tax\nNet income before allocation to noncontrolling interests\n7,812\n8,062\n2,158\nLess: Net income attributable to noncontrolling interests\nNet income attributable to Pfizer Inc. common shareholders\n7,771\n8,031\n2,119\nEarnings per common share––basic\nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n1.37\n1.42\n0.38\nDiscontinued operations––net of tax\nNet income attributable to Pfizer Inc. common shareholders\n1.37\n1.42\n0.38\nEarnings per common share––diluted\nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n1.36\n1.41\n0.37\nDiscontinued operations––net of tax\nNet income attributable to Pfizer Inc. common shareholders\n1.36\n1.41\n0.37\nWeighted-average shares––basic\n5,683\n5,664\n5,643\nWeighted-average shares––diluted\n5,713\n5,700\n5,709\n(a)\nExclusive of amortization of intangible assets.\n(b)\nSee\nNote\n17A\nSee Accompanying Notes.\nPfizer Inc.\n2025 Form 10-K"}]

Derivation: {"current_value": 7771.0, "op": "pct_change", "previous_value": 8031.0}